Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Leah Olivier

Internal Medicine Opelousas, LA Medical Doctor

NPI 1467778662 CMS profile 1117159

539 E Prudhomme St, Opelousas, LA 70570

Open in the dashboard

General payments

$4,116

253 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Leah Olivier of Opelousas, LA is reported in the CMS Open Payments database as having received $4,116 across 253 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $246 13
2021 General $1,359 76
2020 General $1,206 79
2019 General $1,305 85

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Leah Olivier
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Leah Olivier were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Leah Olivier Internal Medicine median Middle half National median
2019 $1,305 $159 $48–$570 $163
2020 $1,206 $119 $33–$402 $114
2021 $1,359 $135 $37–$521 $132
2022 $246 $141 $42–$496 $149
2023 $0 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. GlaxoSmithKline, LLC. $1,375 84 payments
  2. Sunovion Pharmaceuticals Inc. $521 45 payments
  3. AstraZeneca Pharmaceuticals LP $492 26 payments
  4. Mylan Specialty L.P. $432 22 payments
  5. Novartis Pharmaceuticals Corporation $230 13 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $215 13 payments
  7. Genzyme Corporation $94 5 payments
  8. Regeneron Healthcare Solutions, Inc. $85 4 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $76 5 payments
  10. Pfizer Inc. $73 5 payments
  11. Other $523 31 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $4,116 253 payments
Products named General payments · program years 2019–2022
  1. TRELEGY ELLIPTA $895 54 payments
  2. LONHALA MAGNAIR $494 42 payments
  3. Yupelri $262 14 payments
  4. Perforomist $243 13 payments
  5. XOLAIR $230 13 payments
  6. BROVANA $229 17 payments
  7. UTIBRON NEOHALER $229 17 payments
  8. SEEBRI NEOHALER $229 17 payments
  9. SPIRIVA RESPIMAT $215 13 payments
  10. STIOLTO RESPIMAT $201 12 payments
  11. Other $2,832 146 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

117

Median for Internal Medicine: 777

Drug cost

$522

Median for Internal Medicine: $73,373

Branded share of claims

17.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Sertraline Hcl Generic 15 $133
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 21 $109
Pantoprazole Sodium Generic 18 $78
Famotidine Generic 11 $72
Prednisone Generic 24 $54
Levofloxacin Generic 15 $49
Amlodipine Besylate Generic 13 $27

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$111,095

Medicare's payments for the services billed

Medicare patients

202

Average age 78

Services billed

1,327

123 women, 79 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 62%
Ischemic heart disease 57%
Diabetes 52%
Atrial fibrillation 47%
Heart failure 45%
Depression 45%
Chronic kidney disease 42%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

253 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record